1. Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
- Author
-
Pasquale Cioffi, Ettore Cianchetti, Marinella Zilli, Stefano Iacobelli, Giampiero Ausili Cefaro, Roberto Politi, Marta Di Nicola, Camilla Marinelli, Michele De Tursi, Paolo Noccioli, Antonino Grassadonia, Nicola Tinari, Simona Grossi, Domenico Angelucci, Laura Iezzi, Clara Natoli, and Saveria Tavoletta
- Subjects
Oncology ,medicine.medical_specialty ,Time Factors ,Antineoplastic Agents, Hormonal ,Receptor, ErbB-2 ,medicine.medical_treatment ,Anastrozole ,Breast Neoplasms ,Breast Oncology ,Breast cancer ,Surgical oncology ,Internal medicine ,Nitriles ,medicine ,Humans ,Aromatase ,skin and connective tissue diseases ,Neoadjuvant therapy ,Aged ,Neoplasm Staging ,Retrospective Studies ,biology ,business.industry ,Aromatase Inhibitors ,Letrozole ,Carcinoma, Ductal, Breast ,Triazoles ,medicine.disease ,Prognosis ,Neoadjuvant Therapy ,Androstadienes ,Postmenopause ,Survival Rate ,Carcinoma, Lobular ,Tamoxifen ,Hormone receptor ,Chemotherapy, Adjuvant ,biology.protein ,Surgery ,Female ,Neoplasm Grading ,business ,medicine.drug ,Follow-Up Studies - Abstract
Background Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer. Here we report the surgical and long-term outcome of elderly postmenopausal patients with locally advanced, HR-positive breast cancer treated with preoperative AIs. Methods Between January 2003 and December 2012, 144 postmenopausal patients inoperable with breast conservative surgery (BCS) received letrozole, anastrozole, or exemestane as NET. Patients underwent breast surgery and received adjuvant AIs. Adjuvant systemic therapy, chemotherapy and/or trastuzumab, and adjuvant radiotherapy were administered as appropriate, but limited to high-risk patients with few or no comorbidities. Results After a median follow-up of 49 months, 4 (3.0 %) patients had local relapse, 18 (12.5 %) had distant metastases, and 24 (17.0 %) died. BCS was performed in 121 (84.0 %) patients. A tumor size
- Published
- 2014